Cargando…

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy

A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Faieta, Antonio, Dancik, Tavis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939740/
https://www.ncbi.nlm.nih.gov/pubmed/33728076
http://dx.doi.org/10.1155/2021/6640154
_version_ 1783661803950047232
author Faieta, Antonio
Dancik, Tavis
author_facet Faieta, Antonio
Dancik, Tavis
author_sort Faieta, Antonio
collection PubMed
description A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease.
format Online
Article
Text
id pubmed-7939740
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79397402021-03-15 Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy Faieta, Antonio Dancik, Tavis Case Rep Nephrol Case Report A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease. Hindawi 2021-03-01 /pmc/articles/PMC7939740/ /pubmed/33728076 http://dx.doi.org/10.1155/2021/6640154 Text en Copyright © 2021 Antonio Faieta and Tavis Dancik. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Faieta, Antonio
Dancik, Tavis
Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title_full Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title_fullStr Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title_full_unstemmed Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title_short Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
title_sort refractory acute interstitial nephritis in the setting of nivolumab therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939740/
https://www.ncbi.nlm.nih.gov/pubmed/33728076
http://dx.doi.org/10.1155/2021/6640154
work_keys_str_mv AT faietaantonio refractoryacuteinterstitialnephritisinthesettingofnivolumabtherapy
AT danciktavis refractoryacuteinterstitialnephritisinthesettingofnivolumabtherapy